Literature DB >> 10535332

Methionine residue 35 is important in amyloid beta-peptide-associated free radical oxidative stress.

S Varadarajan1, S Yatin, J Kanski, F Jahanshahi, D A Butterfield.   

Abstract

Amyloid beta-peptide (Abeta), the central constituent of senile plaques in Alzheimer's disease (AD) brain, has been shown to be a source of free radical oxidative stress that may lead to neurodegeneration. In the current study Abeta(1-40), found in AD brain, and the amyloid fragment Abeta(25-35) were used in conjunction with electron paramagnetic resonance spin trapping techniques to demonstrate that these peptides mediate free radical production. The methionine residue in these peptides is believed to play an important role in their neurotoxicity. Substitution of methionine by structurally similar norleucine in both Abeta(1-40) and Abeta(25-35), and the substitution of methionine by valine, or the removal of the methionine in Abeta(25-35), abrogates free radical production and protein oxidation of and toxicity to hippocampal neurons. These results are discussed with relevance to the hypothesis that neurodegeneration in Alzheimer's disease may be due in part to Abeta-associated free radical oxidative stress that involves methionine, and to the use of spin trapping methods to infer mechanistic information about Abeta.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10535332     DOI: 10.1016/s0361-9230(99)00093-3

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  29 in total

1.  Despite its role in assembly, methionine 35 is not necessary for amyloid beta-protein toxicity.

Authors:  Panchanan Maiti; Aleksey Lomakin; George B Benedek; Gal Bitan
Journal:  J Neurochem       Date:  2010-03-20       Impact factor: 5.372

Review 2.  Neuroprotective strategies involving ROS in Alzheimer disease.

Authors:  Magali Dumont; M Flint Beal
Journal:  Free Radic Biol Med       Date:  2010-12-01       Impact factor: 7.376

Review 3.  Alzheimer's disease pathologic cascades: who comes first, what drives what.

Authors:  Russell H Swerdlow
Journal:  Neurotox Res       Date:  2011-09-13       Impact factor: 3.911

4.  Ab initio modelling of the structure and redox behaviour of copper(I) bound to a His-His model peptide: relevance to the beta-amyloid peptide of Alzheimer's disease.

Authors:  Duilio F Raffa; Gail A Rickard; Arvi Rauk
Journal:  J Biol Inorg Chem       Date:  2006-09-30       Impact factor: 3.358

Review 5.  APP/Aβ structural diversity and Alzheimer's disease pathogenesis.

Authors:  Alex E Roher; Tyler A Kokjohn; Steven G Clarke; Michael R Sierks; Chera L Maarouf; Geidy E Serrano; Marwan S Sabbagh; Thomas G Beach
Journal:  Neurochem Int       Date:  2017-08-12       Impact factor: 3.921

Review 6.  The role of iron and copper in the aetiology of neurodegenerative disorders: therapeutic implications.

Authors:  George Perry; Lawrence M Sayre; Craig S Atwood; Rudolph J Castellani; Adam D Cash; Catherine A Rottkamp; Mark A Smith
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

7.  Amyloid β-peptide 1-42 modulates the proliferation of mouse neural stem cells: upregulation of fucosyltransferase IX and notch signaling.

Authors:  Yutaka Itokazu; Robert K Yu
Journal:  Mol Neurobiol       Date:  2014-01-17       Impact factor: 5.590

Review 8.  Amyloid β-peptide (1-42)-induced oxidative stress in Alzheimer disease: importance in disease pathogenesis and progression.

Authors:  D Allan Butterfield; Aaron M Swomley; Rukhsana Sultana
Journal:  Antioxid Redox Signal       Date:  2013-02-14       Impact factor: 8.401

Review 9.  Roles of amyloid beta-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment.

Authors:  D Allan Butterfield; Tanea Reed; Shelley F Newman; Rukhsana Sultana
Journal:  Free Radic Biol Med       Date:  2007-06-13       Impact factor: 7.376

10.  Reduction of oxidative stress, amyloid deposition, and memory deficit by manganese superoxide dismutase overexpression in a transgenic mouse model of Alzheimer's disease.

Authors:  Magali Dumont; Elizabeth Wille; Cliona Stack; Noel Y Calingasan; M Flint Beal; Michael T Lin
Journal:  FASEB J       Date:  2009-04-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.